Roche Raises Illumina Bid to $51, Seeking to Accelerate Deal

Roche Raises Illumina Bid to $51, Seeking to Accelerate Deal

JB Reed/Bloomberg

Tablets of Roche Holding AG's Tarceva cancer drug are arranged for a photograph.